Trial · NCT07905560
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 1) | Baseline up to Follow-Up (From Day -28 (Screening) to Day 37 (FUP visit) | |
| Primary | Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 2) | From Day -28 (Screening) to Day 60 (FUP visit) | |
| Primary | Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 3) | From Day -28 (Screening) to Day 119 (FUP visit) | |
| Primary | Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 4) | From Day -28 (Screening) to Day 37 (FUP visit) | |
| Primary | Cmax measurement of SUN-0864 in Part 4 | up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3. | |
| Primary | Tmax measurement of SUN-0864 in Part 4 | up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3. | |
| Primary | t1/2 measurement of SUN-0864 in Part 4 | up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3. | |
| Primary | AUClast measurement of SUN-0864 in Part 4 | up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3. | |
| Primary | AUCinf measurement of SUN-0864 in Part 4 | up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3. | |
| Primary | AUC24 measurement of SUN-0864 in Part 4 | up to 24 hours post-dose. Daily from Day 1 (Predose) to Day 3. | |
| Secondary | Change from Baseline in body weight in Part 3 | Baseline to Follow-up, up to Day 119 | |
| Secondary | Cumulative percentage fraction of the drug Excreted in Urine Over the Dosing Interval (Fe) in Part 2 | Pre-dose to 24 hours post-dose on Day 28 | |
| Secondary | Renal Clearance (CLr) in Part 2 | Pre-dose to 24 hours post-dose on Day 28 | |
| Secondary | Plasma PK parameters Cmax (Part 1) | up to 48 hours post-dose on Day 1 of each Period (Part 1). Daily from Day 1 (Predose) to Day 3. | |
| Secondary | Plasma PK parameters Cmax (Part 2) | 48 hours post-dose on Day 30 (Part 2). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07905560/registered